12 Dec, 10:04 - Indian

SENSEX 81562.27 (0.04)

Nifty 50 24634.95 (-0.03)

Nifty Bank 53378.7 (-0.02)

Nifty IT 45956.2 (1.34)

Nifty Midcap 100 59317.55 (0.04)

Nifty Next 50 73233.55 (-0.08)

Nifty Pharma 22325.25 (0.10)

Nifty Smallcap 100 19638 (-0.10)

12 Dec, 10:04 - Global

NIKKEI 225 39902.13 (1.35)

HANG SENG 20501.14 (1.72)

S&P 6096.75 (-0.13)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(21 Nov 2024, 10:23)

DRL slips after Hyderabad facility gets 7 observations from USFDA

Dr Reddy’s Laboratories (DRL) declined 1.07% to Rs 1200.95 after the US Food and Drug Administration (USFDA) concluded its Good manufacturing practice (GMP) inspection with seven observations at API manufacturing facility in Bollaram, Hyderabad.


The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issued Form-483 with 7 observations.

Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.

The company’s consolidated net profit declined 15.3% to Rs 1255.70 crore despite of 16.5% jump in revenue from operations to Rs 8016.10 crore in Q2 FY25 over Q2 FY24.

More News
More Company News View Company Information